LetterMycophenolate mofetil and hydroxychloroquine: An effective treatment for recalcitrant cutaneous lupus erythematosus
References (3)
- et al.
Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus
J Am Acad Dermatol
(2011)
Cited by (9)
Cutaneous lupus erythematosus: A review of the literature
2019, International Journal of Women's DermatologyCitation Excerpt :A retrospective analysis of 24 patients with treatment-resistant CLE showed some clinical response in all patients and resolution or near resolution of disease activity in 62% of patients (Gammon et al., 2011). MMF in combination with hydroxychloroquine has been trialed successfully in a small case series of three cases (Sadlier et al., 2012). Case reports have shown successful treatment of DLE lesions with azathioprine (Okon and Werth, 2013); however, there are no controlled trials to support routine use in CLE.
Which dose of steroids and which cytotoxics for severe lupus?
2014, Presse MedicaleCitation Excerpt :Cutaneous improvement is usually noticeable within 2 months of treatment. The evidence supporting the management of severe cutaneous and discoid lupus erythematosus with mycophenolate mofetil is based on open label placebo-controlled trials, case series and case reports, which recommend an average dose of MMF 1–3 g per day [36–39]. Clinical response may take approximately 3 months to become evident.
Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus
2013, Autoimmunity ReviewsCitation Excerpt :Other immunosuppressive drugs not yet approved for the treatment of CLE are MMF and EC-MPS. So far, there are only a few case reports and retrospective studies showing that MMF is effective in treating different subtypes of CLE and skin manifestations in SLE [7,52,53]. In general, MMF is well tolerated.
An update on the management of refractory cutaneous lupus erythematosus
2022, Frontiers in MedicineCutaneous Lupus Erythematosus: Progress and Challenges
2020, Current Allergy and Asthma ReportsS2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)
2017, Journal of the European Academy of Dermatology and Venereology
Funding sources: None.
Conflicts of interest: None declared.